FIELD: biotechnology.
SUBSTANCE: presented is an canine IL-4 receptor antibody which blocks binding of said receptor with canine interleukin-4. Also disclosed is use of the antibody of the present invention in treating asthma and atopic dermatitis in dogs.
EFFECT: invention provides binding with canine IL-4 high-affinity alpha-receptor.
11 cl, 6 dwg, 5 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CANINE ALPHA INTERLEUKIN-4 RECEPTOR ANTIBODIES | 2020 |
|
RU2840044C1 |
| ANTIBODIES TO CANINE PD-1 | 2014 |
|
RU2761663C2 |
| CANINE ALPHA INTERLEUKIN-4 RECEPTOR ANTIBODIES | 2020 |
|
RU2838943C1 |
| ANTIBODIES TO DOGS' PD-1 | 2014 |
|
RU2732604C2 |
| ANTI-CANINE CTLA-4 ANTIBODY | 2020 |
|
RU2818586C2 |
| ANTIBODIES OF DOGS WITH MODIFIED CH2-CH3 SEQUENCES | 2014 |
|
RU2687209C1 |
| PD-L1 ANTIBODIES BINDING CANINE PD-L1 | 2015 |
|
RU2832918C2 |
| PD-L1 ANTIBODIES BINDING DOG PD-L1 | 2015 |
|
RU2722562C2 |
| CANINISED MURINE ANTIBODIES TO HUMAN PD-1 | 2014 |
|
RU2676158C1 |
| MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN-31 | 2012 |
|
RU2588462C2 |
